Korean J Gastroenterol.  2015 Jan;65(1):1-3. 10.4166/kjg.2015.65.1.1.

The Possibility of Tenofovir Monotherapy as a Rescue Therapy in Patients with Chronic Hepatitis B

• Kim CW

• KMID: 2373173
• DOI: http://doi.org/10.4166/kjg.2015.65.1.1

Abstract

No abstract available.

Reference

References

1. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 1999; 341:1256–1263.

2. Park NH, Shin JW, Park JH, et al. Predictive factors and efficacy of lamivudine treatment in chronic hepatitis B infection. Korean J Gastroenterol. 2003; 42:303–312.

3. Scaglione SJ, Lok AS. Effectiveness of hepatitis B treatment in clinical practice. Gastroenterology. 2012; 142:1360–1368.

4. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology. 2003; 125:1714–1722.

5. Yoon SK, Jang JW, Kim CW, et al. Long-term results of lamivudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B: response and relapse rates, and factors related to durability of HBeAg seroconversion. Intervirology. 2005; 48:341–349.

6. Peters MG, Hann HW, Martin P, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-re-sistant chronic hepatitis B. Gastroenterology. 2004; 126:91–101.

7. Yeon JE, Yoo W, Hong SP, et al. Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil. Gut. 2006; 55:1488–1495.

8. Lee YS, Suh DJ, Lim YS, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology. 2006; 43:1385–1391.

9. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg- negative chronic hepatitis B. Hepatology. 2007; 45:307–313.

10. Yim HJ, Seo YS, Yoon EL, et al. Adding adefovir vs. switching to entecavir for lamivudine-resistant chronic hepatitis B (ACE study): a 2-year follow-up randomized controlled trial. Liver Int. 2013; 33:244–254.

11. Baran B, Soyer OM, Ormeci AC, et al. Efficacy of tenofovir in patients with Lamivudine failure is not different from that in nucleoside/nucleotide analogue-naive patients with chronic hepatitis B. Antimicrob Agents Chemother. 2013; 57:1790–1796.

12. Seto WK, Liu K, Wong DK, et al. Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment. J Hepatol. 2013; 59:709–716.

13. Fung S, Kwan P, Fabri M, et al. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 2014; 146:980–988.

14. Qi X, Xiong S, Yang H, Miller M, Delaney WE 4th. In vitro suscepti-bility of adefovir-associated hepatitis B virus polymerase mutations to other antiviral agents. Antivir Ther. 2007; 12:355–362.

15. Berg T, Zoulim F, Moeller B, et al. Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients. J Hepatol. 2014; 60:715–722.

16. van Bömmel F, de Man RA, Wedemeyer H, et al. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology. 2010; 51:73–80.

17. Choi K, Lee HM, Jun BG, et al. Efficacy of tenofovir-based rescue therapy for patients with drug-resistant chronic hepatitis B. Korean J Gastroenterol. 2015; 65:35–42.